About Jade Biosciences, Inc.
https://jadebiosciences.comJade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy.
CEO
Tom Frohlich
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-04-29 | Reverse | 1:35 |
ETFs Holding This Stock
Summary
Showing Top 3 of 46
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
FMR LLC
Shares:4.89M
Value:$71.67M
FAIRMOUNT FUNDS MANAGEMENT LLC
Shares:3.22M
Value:$47.21M
VR ADVISER, LLC
Shares:3.22M
Value:$47.21M
Summary
Showing Top 3 of 79
About Jade Biosciences, Inc.
https://jadebiosciences.comJade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $27.39M ▼ | $-25.18M ▲ | 0% | $-0.64 ▲ | $-25.16M ▲ |
| Q2-2025 | $0 | $27.78M ▲ | $-32.13M ▼ | 0% | $-1.13 ▲ | $-32.13M ▼ |
| Q1-2025 | $0 | $3.38M ▼ | $-2.52M ▲ | 0% | $-3.04 ▲ | $-2.51M ▲ |
| Q4-2024 | $0 | $6.39M ▼ | $-5.43M ▲ | 0% | $-6.56 ▼ | $-5.37M ▲ |
| Q3-2024 | $0 | $14.96M | $-16.28M | 0% | $-5.16 | $-16.28M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $198.91M ▼ | $202.45M ▼ | $23.1M ▲ | $179.35M ▼ |
| Q2-2025 | $220.94M ▲ | $223.97M ▲ | $22.41M ▲ | $201.56M ▲ |
| Q1-2025 | $76.21M ▼ | $77.53M ▼ | $2.49M ▼ | $75.05M ▼ |
| Q4-2024 | $78.62M ▼ | $80.33M ▼ | $3.9M ▼ | $76.43M ▼ |
| Q3-2024 | $88.73M | $90.96M | $10.47M | $80.49M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-25.18M ▲ | $-22.12M ▲ | $-148.71M ▼ | $0 ▼ | $-170.84M ▼ | $-22.18M ▲ |
| Q2-2025 | $-32.13M ▼ | $-36.53M ▼ | $-12.99M ▼ | $190.61M ▲ | $176.72M ▲ | $-36.67M ▼ |
| Q4-2024 | $-5.43M ▲ | $-11.05M ▼ | $13.13M ▲ | $554K ▼ | $2.64M ▲ | $-11.05M ▼ |
| Q3-2024 | $-16.28M ▲ | $37.3M ▲ | $-26.83M ▼ | $69.92M ▲ | $46K ▼ | $37.3M ▲ |
| Q2-2024 | $-24.77M | $-20.43M | $18M | $24.38M | $21.95M | $-20.43M |
CEO
Tom Frohlich
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-04-29 | Reverse | 1:35 |
ETFs Holding This Stock
Summary
Showing Top 3 of 46
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
FMR LLC
Shares:4.89M
Value:$71.67M
FAIRMOUNT FUNDS MANAGEMENT LLC
Shares:3.22M
Value:$47.21M
VR ADVISER, LLC
Shares:3.22M
Value:$47.21M
Summary
Showing Top 3 of 79